8-K: AptarGroup Reports Q2 2026 Results, Sales Exceed $1 Billion

AptarGroup announced its second quarter 2026 financial results, with reported sales surpassing $1 billion for the first time, driven by growth across all segments, particularly in Pharma and Closures.

Summary

• AptarGroup reported second quarter 2026 sales of $1.03 billion, a 6% increase over the prior year, marking the first time sales have exceeded $1 billion.
• Core sales increased by 1% year-over-year.
• Reported net income was $88 million, with reported earnings per share of $1.36.
• Adjusted earnings per share (EPS) were $1.42.
• Adjusted EBITDA margin was 20.7%, down from 22.6% in the prior year.
• The company returned $81 million to shareholders through share repurchases and dividends in the quarter.
• Sales growth was observed across all three segments: Pharma (4% reported, 1% core), Beauty (10% reported, 1% core), and Closures (7% reported, 4% core).
• For the first six months of 2026, reported sales increased 8% to $2.01 billion, while reported EPS decreased 12% to $2.48.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with the achievement of over $1 billion in sales being a key highlight, though margin compression and a decrease in EPS year-over-year temper the overall sentiment.

Positives

• Reported sales exceeded $1 billion for the first time, reaching $1.03 billion in Q2 2026.
• Revenue growth was achieved across all three business segments: Pharma, Beauty, and Closures.
• Aptar Pharma demonstrated strong performance with double-digit growth in consumer healthcare and high single-digit growth in injectables and prescription, excluding emergency medicine.
• Beauty segment growth was supported by strong demand in prestige fragrance solutions.
• Closures segment benefited from continued strength in beverage dispensing, including a new dispensing closure innovation.
• The company returned $81 million to shareholders in the quarter and $212 million year-to-date via share repurchases and dividends.
• Outlook for Q3 2026 is positive, with expectations of solid growth across all segments.

Negatives

• Adjusted EBITDA margin decreased to 20.7% from 22.6% in the prior year quarter.
• Reported earnings per share decreased to $1.36 in Q2 2026 from $1.67 in Q2 2025.
• Adjusted earnings per share decreased to $1.42 in Q2 2026 from $1.68 in Q2 2025.
• Pharma segment's reported sales growth was impacted by a 2% currency headwind and a 1% decrease from acquisitions.
• Beauty segment's adjusted EBITDA margin declined by 190 basis points due to lower product volumes and unfavorable mix.
• Closures segment's adjusted EBITDA margin declined by 200 basis points due to production ramp-ups and maintenance.
• Year-to-date reported EPS decreased by 12% compared to the prior year.

Risks

• Geopolitical conflicts worldwide and their indirect impact on customer demand and rising input costs.
• Cybersecurity threats that could impact networks and reporting systems.
• Availability of raw materials and components, particularly from sole-sourced suppliers.
• Litigation involving intellectual property rights and the outcome of ongoing legal proceedings.
• Economic recession globally or in key markets, leading to lower demand and asset utilization.
• Fluctuations in foreign currency exchange rates and the effective tax rate.
• Supply chain disruptions, labor shortages, and rising transportation and input costs.
• Potential for significant product liability claims and difficulties in product development.

Future Outlook

Aptar expects solid growth across all three segments in the third quarter of 2026. Pharma anticipates continued performance in injectables and consumer healthcare, with prescription dispensing systems remaining strong, and emergency medicine headwinds expected to abate by Q4. Beauty expects growth in fragrance and facial skincare. Closures anticipate continued strong demand and improving operational performance. Third quarter 2026 adjusted EPS is projected to be in the range of $1.45 to $1.53.

Management Comments

• "We were pleased to deliver revenue growth across all three segments during the quarter."
• "While margins are currently impacted by product mix and operational factors, we remain confident in the company's long-term margin structure, supported by strong demand trends across key Pharma franchises, continued momentum in Closures, and the actions underway to enhance operational performance."
• "As I conclude my tenure as CEO at Aptar, I am pleased to hand the company over following a quarter that reflects solid performance, a strong balance sheet and an improving growth trajectory in the outlook."
• "These results demonstrate the dedication of our teams, the strength of our innovation-led portfolio and our ability to create value for customers across attractive end markets."
• "In alignment with Gael Touya, who will assume the role of CEO on September 1, we enter the third quarter with confidence."

Industry Context

StockSavvy.ai notes that AptarGroup's performance in Q2 2026, particularly its ability to cross the $1 billion sales threshold, highlights its resilience and market leadership in specialized dispensing technologies. The company's segment performance reflects broader trends in healthcare demand (Pharma), premium consumer goods (Beauty), and essential packaging (Closures).

Comparison to Industry Standards

• No direct comparisons to specific global benchmarks or named competitors were provided in the filing.
• The filing focuses on AptarGroup's internal performance metrics and year-over-year comparisons.

Management Changes

Legal Proceedings

• Lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar's claims of trade-secret misappropriation and contractual breaches, and ARS's lawsuit against Aptar under U.S. antitrust laws.
• Patent infringement actions filed by Nemera La Verpillire SAS in Germany and France relating to certain of Aptar's ophthalmic products.

Stakeholder Impact

• Shareholders: Benefit from $81 million returned in Q2 2026 and $212 million year-to-date through share repurchases and dividends, with a positive outlook for future growth.
• Employees: The company highlights the dedication of its teams and the strength of its innovation-led portfolio.
• Customers: Aptar partners with top healthcare and consumer brands, providing innovative solutions across Pharma, Beauty, and Closures segments.
• Suppliers: Potential risks related to the availability of raw materials and the financial viability of suppliers are noted.

Next Steps

• Continue to monitor the abatement of emergency medicine destocking headwinds, expected by Q4 2026.
• Observe the integration and performance of acquired businesses.
• Track the impact of operational improvements and cost containment initiatives on margins.
• Monitor the successful ramp-up of new production lines in the Closures segment.
• Prepare for the CEO transition on September 1, 2026.

Key Dates

Recommendation

The company achieved a significant sales milestone, and the outlook is positive with expected growth across segments. However, the decrease in margins and EPS compared to the prior year, coupled with ongoing legal proceedings and industry-wide risks, warrant a cautious 'hold' stance until these pressures are fully resolved and margin recovery is evident.

Keywords

drug delivery, dosing technologies, protection technologies, consumer product dispensing, Pharma, Beauty, Closures, dispensing solutions